<DOC>
	<DOCNO>NCT02444767</DOCNO>
	<brief_summary>The Bimatoprost Ocular Insert intend provide sustain delivery bimatoprost ocular surface lower intraocular pressure ( IOP ) patient open-angle glaucoma ocular hypertension . This study evaluate pharmacokinetic aspect Bimatoprost Ocular Insert healthy ( non-glaucoma ) subject .</brief_summary>
	<brief_title>Bimatoprost Ocular Insert Pharmacokinetic Study</brief_title>
	<detailed_description>This study design provide pharmacokinetic ( PK ) data respect relative systemic exposure bimatoprost bimatoprost acid administration single 13 mg Bimatoprost Ocular Insert 1 week medically stable adult subject without primary open angle glaucoma ( POAG ) ocular hypertension ( OHT ) .</detailed_description>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>1 . Male female subject age 18 55 year , inclusive . 2 . Subjects medically stable without POAG OHT . 3 . Written inform consent participate study . 4 . Body mass index 18 30 kg/m² , inclusive . 5 . Female subject childbearing potential — surgically sterile least 2 year postmenopausal — must agree utilize one follow form contraception screen completion study : abstinence , intrauterine device vasectomize partner ( 6 month minimum ) . 1 . A history clinically significant gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , immunologic , psychiatric , cardiovascular disease condition , opinion Principal Investigator , would jeopardize safety subject impact validity study result . 2 . A history allergic adverse response bimatoprost comparable similar product . 3 . Subjects unable tolerate Inserts contain drug 7 day trial wear period . 4 . Subjects require two ( 2 ) siteassisted replacement insert contain drug 7 day trial wear period . 5 . Subjects require contact lens use study period . 6 . Subjects currently punctal occlusion one eye . 7 . Subjects make blood donation one ( 1 ) pint within 30 day prior study initiation . 8 . Subjects make plasma donation within 14 day study initiation . 9 . Participation clinical trial within 30 day prior first dose Study Drug . 10 . Use overthecounter ( OTC ) medication , include vitamin , herbal product , dietary supplement , study . 11 . Use prescription medication medication washout ( screen ) period study . 12 . Required use study ocular medication artificial tear . 13 . Ocular , orbital , and/or eyelid surgery type within past 6 month screen date . 14 . Past history incisional surgery glaucoma time . 15 . Past history corneal refractive surgery . 16 . Any active ocular disease opinion Investigator would interfere conduct study ( e.g. , severe dry eye , uveitis , inflammation , ocular infection , corneal edema ) . Patients may mild blepharitis , mild dry eye , cataract , agerelated macular degeneration background diabetic retinopathy , opinion Investigator , would interfere conduct study . 17 . Smoking use tobacco product product contain nicotine within 6 month prior study . 18 . Female subject lactate . 19 . Positive pregnancy test prior administration Study Insert woman childbearing potential . 20 . Positive urine screen alcohol , drug abuse , cotinine . 21 . Subjects POAG OHT , opinion investigator , would unsafe discontinue ocular hypotensive treatment require period study . 22 . Significant risk angle closure due pupil dilation , define Shaffer classification less grade 2 base gonioscopy perform within last 12 month . 23 . Subjects ocular hypotensive treatment fully wash prior receive active insert .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>